Research Protocol on the Benefits of Granulocyte Colony-Stimulating Factor in Post-Chemotherapy Treatment for Adults with De Novo Acute Myeloid Leukemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600116861

Enrollment

Unknown

Registered

2026-01-15

Start date

2026-01-20

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Interventions

Control Group:none

Treatment Group:Human Granulocyte Colony-stimulating Factor Injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18 years; 2. Newly diagnosed AML (non-APL); 3. Planned to receive induction therapy. 4. Willing to participate in the long-term study and able to understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Prior anti-leukemia treatment; 2. Concurrent other malignant tumors; 3. Opting for supportive therapy alone.

Design outcomes

Primary

Measure	Time frame
Absolute Neutrophil Count;Infection Event;	—

Secondary

Measure	Time frame
Remission Rate;survival rate;	—

Countries

China

Contacts

Public ContactYantao Ling

West China Hospital of Sichuan University

834540872@qq.com+86 28 8542 2366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026